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Background and purpose Single fraction treatments of 15Gy or 19Gy are 
common in HDR prostate brachytherapy. In-vivo dosimetry (IVD) is 
therefore important to ensure patient safety. This study assesses clinical IVD 
and investigates error detection thresholds for real-time treatment 
monitoring. 
 
Material and methods IVD was performed for 40 treatments planned using 
intra-operative trans-rectal ultrasound (TRUS) with a MOSFET inserted 
into an additional needle. Post-treatment TRUS images were acquired for 20 
patients to assess needle movement. Monte Carlo simulations of treatment 
plans were performed for 10 patients to assess impact of heterogeneities. 
Per-needle and total plan uncertainties were estimated and retrospectively 
applied to the measured data as error detection thresholds.  
 
Results The mean measured dose was -6.4% compared to prediction (range 
+5.1% to -15.2%). Needle movement and heterogeneities accounted for -
1.8% and -1.6% of this difference respectively (mean values for the patients 
analysed). Total plan uncertainty (k=2) ranged from 11% to 17% and per 
needle uncertainty (k=2) ranged from 18% to 110% (mean 31%). One out of 
40 plans and 5% of needles were outside k=2 error detection threshold.  
 
Conclusions IVD showed good agreement with predicted dose within 
measurement uncertainties, providing reassurance in the accuracy of dose 
delivery. Thresholds for real-time error detection should be calculated on an 
individual plan/needle basis. 
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Introduction 
Evidence of the dose-response relationship in prostate cancer [1] has led to 
increases in the dose per fraction delivered in high dose rate (HDR) prostate 
brachytherapy with up to 19 Gy prescribed to the 100% isodose in some 
monotherapy treatments [2]. It is therefore important to have confidence in 
the dose that is being delivered and there is increasing interest in performing 
in-vivo dosimetry (IVD) [3,4]. UK guidelines recommend that IVD is 
performed for most radiotherapy patients at the beginning of their treatment 
[5]. HDR prostate brachytherapy treatments use a single source sequentially 
stepping through a set of needles and so it could be possible to monitor the 
treatment in real-time and interrupt and correct if a significant error is 
detected. In this study the feasibility of this approach is investigated using 
clinical IVD data from 40 HDR prostate brachytherapy patients. 
 
IVD in HDR prostate brachytherapy has been implemented by Suchowerska 
et al [6] using a scintillation detector in the urethral catheter and by 
Seymour et al [7] using a diode array inside a dummy ultrasound probe in 
the rectum, however these studies did not analyse measured data in terms of 
real-time per-needle measurements. TLDs have given good results for HDR 
prostate brachytherapy IVD [8-10] but do not allow a real time 
measurement approach. Haughey et al [11] used a metal-oxide 
semiconductor field effect transistor (MOSFET) linear array inside the 
rectum during HDR prostate brachytherapy but concluded that the approach 
was not suitable due to the difficulties of quantifying uncertainties in 
MOSFET response. IVD in permanent seed implant prostate brachytherapy 
has also been investigated [12-14]. 
 
Dose gradients and position uncertainties of sources and detectors result in 
large and variable uncertainties in brachytherapy IVD. Real-time IVD error 
detection cannot use a simple error threshold but requires uncertainties to be 
estimated for individual catheters based on treatment plan data. This was 
demonstrated by Kertscher et al [15] who used Monte Carlo (MC) 
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simulations of random source position shifts to estimate uncertainties that 
were applied to measurements with simulated treatment errors.  
 
In this study we report our clinical experience of IVD using a 
microMOSFET (model TN-502RDM-H Best Medical, Ottawa, Canada, 
hereafter referred to as MOSFET) inserted into an additional needle during 
intra-operative trans-rectal ultrasound (TRUS) based HDR prostate 
brachytherapy. An uncertainty analysis is performed including MC 
simulations to assess the impact of heterogeneities on dose, post-treatment 
imaging to assess the impact of needle movement between planning and 
treatment delivery, evaluation of position dependent uncertainties and other 
MOSFET and dose calculation related uncertainties. The uncertainty 
analysis is used to define error detection thresholds for per-needle and total 
plan measurements, and these thresholds are retrospectively applied to the 
IVD results to assess the feasibility of real-time treatment monitoring.   
 
Method 
 
MOSFET calibration and commissioning 
MOSFET calibration and commissioning used a 30 cm x 30 cm x 30 cm 
water tank with additional solid water underneath to ensure adequate scatter. 
The tank was fitted with two aligned template grids through which steel 
needles were inserted to create an accurate, rigid geometry. All 
measurements were performed using the same Flexitron afterloader (Elekta 
AB, Stockholm, Sweden) and 192Ir source used in clinical treatments. For 
calibration, the MOSFET was placed in a central steel needle and was 
irradiated using 4 needles arranged at cardinal angles around the MOSFET 
needle, to minimize dose gradient at the MOSFET position, and with a 
source-MOSFET distance of 1.5 cm to minimize the energy dependence 
correction that would need to be applied to clinical measurements. The 
MOSFET sensitivity factor was determined from the ratio of the MOSFET 
reading to the expected dose calculated using MC simulation of the water 
tank setup, using the MC simulation framework described below. Three 
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repeated measurements of ~2Gy were taken. Calibration measurements 
were repeated 4-5 times through the MOSFET lifetime of 20000mV to 
assess fade in response with accumulated mV. Additional details on 
calibration are included in supplementary material. 
 
The water tank was also used to investigate other properties of MOSFET 
response. A correction for energy dependence of MOSFET response was 
determined from measurements varying the source-MOSFET distance 
between 1 cm and 5 cm - additional details are included in supplementary 
material. Angular dependence was tested by fixing the MOSFET in a single 
position and irradiating from source positions at a range of polar and 
azimuthal angles. Linearity of response was tested by delivering doses from 
0.1 - 20 Gy to the MOSFET. Temperature dependence between room 
temperature used for calibration and body temperature was tested by 
repeating calibration measurements with the water at 37 °C and allowing the 
MOSFET to stabilize at this temperature for 10 minutes.  
 
Clinical measurements 
IVD measurements were performed for 40 prostate cancer patients with 
intermediate or high risk disease treated between July 2014 and September 
2015. Thirty-three patients received a single fraction boost followed by 37.5 
Gy in 15 fractions of external beam to the prostate and seminal vesicles [16] 
and 7 patients received a single fraction monotherapy treatment [2]. Plans 
were prescribed to the prostate D90, with 15 Gy and 19 Gy to the 100% 
isodose levels for boost and monotherapy treatments respectively. Needles 
were inserted under TRUS guidance, treatments were planned from TRUS 
images using the Oncentra Prostate treatment planning system (TPS) 
v4.1.3 (Elekta AB), DVH-based inverse optimisation (referred to as DVHO 
in Oncentra Prostate[17] and delivered in a single theatre session with 
the patient remaining in the same position with ultrasound probe in-situ for 
the entire procedure. Treatments were delivered using a Flexitron 
afterloader (Elekta AB) and stainless steel needles (interstitial bevel needle 
product number 083.045, Elekta AB). Needles are inserted approximately 1 
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cm apart around the periphery of the prostate with 2-5 needles inserted more 
centrally for dose coverage of the base and apex of the gland. Dwell 
positions were activated throughout the PTV with 2 mm spacing. Plan 
objectives were prostate V100 > 95%, PTV V100 > 95% (PTV = prostate + 3 
mm, 0 mm posteriorly). Constraints were urethra D10 <17.5 Gy and rectum 
D2cm3 < 11.8 Gy, V100 = 0 for boost [16] and urethra D10 <22 Gy, D30 
<20.8 Gy, V150 = 0 and rectum D2cm3 < 15 Gy, V100 = 0 for monotherapy 
[2].  
 
For IVD the MOSFET was inserted into an additional needle placed below 
or to the side of the urethra. The central position allows the MOSFET to 
sample as equal as possible dose contribution from each treatment needle, 
and reduces the dose gradient at the MOSFET position. The MOSFET 
needle is inserted to depth ~1 cm caudal to the prostate base, sufficient for 
the MOSFET to reach mid-gland and for the needle to be clearly 
distinguished from treatment needles (as it protrudes ~2cm further from the 
template) to reduce the risk of accidental connection to the afterloader. For 
simplicity the centre of the MOSFET bulb is always inserted 189 mm into 
the (200 mm long) needle, this corresponds to the most distal needle source 
position and allows the MOSFET position to be reconstructed using the 
source positions defined  in the TPS. After the treatment plan is approved 
and before treatment delivery, the expected MOSFET reading is determined 
as follows. The contribution to the dose at the MOSFET position from each 
individual source dwell position is exported from the TPS, along with the 
MOSFET and source co-ordinates. The predicted MOSFET accumulated 
mV reading is calculated by multiplying each individual dweOOSRVLWLRQ¶V
planned dose contribution to the MOSFET by the MOSFET mV/Gy 
sensitivity factor DQGDFRUUHFWLRQIRUWKH026)(7¶VHQHUJ\GHSHQGHQW
response. An example patient case is included in supplementary material. 
Per-needle and total plan readings are calculated by summing the individual 
dwell position contributions.  
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The MOSFET is inserted after the treatment needles have been connected to 
the afterloader, ~10 minutes before treatment starts. A mark on the 
MOSFET cable 189 mm back from the MOSFET is lined up to the edge of 
the needle, to ensure correct insertion depth. The MOSFET reader takes a 
reading every 20 s and is monitored remotely by camera during treatment. 
The Flexitron takes > 20 s between each needle delivery allowing the per 
needle mV reading to be determined.  
 
Monte Carlo simulations 
MC simulations were performed for 10 patient plans to determine the 
impact of heterogeneities on dose at the MOSFET position. DICOM 
treatment plan data were exported from the TPS into an MC simulation 
framework that has previously been described [18] using the Flexitron 
source modeled and benchmarked using data from AAPM report 229 [19] 
and using MCNPX v2.5.0 [20]. The simulation model included ANSI 
303/304 steel needles modeled with density 8.02 gcm-3 and prostate tissue 
with density 1.04 gcm-3 and composition as recommended in TG-186 
(AAPM Task Group No. 186 Report) [21] Table III. Dose at the MOSFET 
position was calculated using a 1 mm diameter spherical water cell 
(MCNPX F6 tally) and 200-400 million histories (depending on the implant 
size) were simulated to achieve statistical uncertainty in the tally cell of 
~0.5%.  
 
Analysis of post-treatment imaging 
To assess the impact of needle movement between planning TRUS image 
acquisition and treatment (typically ~1 hour), for 20 of the patients, a TRUS 
volume was acquired immediately after completion of treatment. The 
needles were reconstructed in the post-treatment images, the dose at the 
MOSFET position was recalculated using the adjusted needle positions and 
compared to the original planned dose. 
 
Uncertainty analysis 
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An uncertainty analysis was performed to estimate per-needle and total plan 
error detection thresholds. Table 1 lists the uncertainty components included 
in the analysis. MOSFET calibration uncertainty was estimated from the 
standard error of repeated measurements. Energy dependence correction 
uncertainty was estimated as the standard error of the actual corrections 
applied across all patients. An uncertainty of 3% for anisotropic response 
was included in the per-needle uncertainty as this was the level of repeat 
measurement uncertainty in the commissioning anisotropy measurements. 
For total plan measurements this was not included as the central MOSFET 
measurement position should ensure any small angular variations in 
response average out. Source calibration and TPS dose calculation 
uncertainties were taken from published data [22]. MOSFET reproducibility 
uncertainty was calculated from the predicted reading for each needle/plan 
using data on the standard error of sets of repeated measurements at 
different dose levels, described in supplementary data.  
 
Position uncertainty was calculated for each needle/plan based on the source 
positions and predicted dose contributions as follows. A source-MOSFET 
distance uncertainty threshold of 1mm was used as a study by Milickovic et 
al [23] found needle shifts of 1 mm on average between planning and 
treatment in TRUS based HDR prostate brachytherapy, and that this level of 
shift did not have clinically significant impact on plan dosimetry. For each 
source position the impact of ±1 mm shifts in the source-MOSFET distance 
was estimated using inverse square law. The per-needle and total plan 
position uncertainties were then estimated by taking a weighted average of 
the uncertainty for each source position (weighted by the dose per source 
position as a proportion of the total dose). For the total plan uncertainty, this 
weighted average was divided by the square root of the number of needles 
in the plan as the uncertainties associated with individual needles are not 
independent, for example if the MOSFET moves closer to one needle it will 
move further from another. An example position uncertainty calculation is 
included in supplementary data. All uncertainty components were combined 
in quadrature and the result multiplied by 2 to give the k=2 value. 
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Evaluation of error detection thresholds 
The measured clinical data was retrospectively compared to the calculated 
uncertainty values to evaluate the use of error detection thresholds for real-
time decision making. Firstly the mean corrections determined from the MC 
simulation and post-treatment imaging investigations described above were 
applied as a fixed percentage correction across all per-needle and total plan 
measurements. Measurements were considered to exceed the threshold if the 
percentage difference between measured and predicted values exceeded the 
k=2 uncertainty for the needle or plan.  
 
Results 
 
MOSFET calibration and commissioning 
MOSFET sensitivity factors used in the clinical measurements ranged from 
89.7 mV/Gy - 96.1 mV/Gy. Sensitivity factors were found on average to 
decrease by 0.24 mV/Gy for every 1000 accumulated mV. Energy 
dependence correction measurements showed the MOSFETs to over-
respond by 2.6% cm-1 increase in source-MOSFET distance. The MOSFET 
response was linear up to 20 Gy. Angular variation of MOSFET response 
was less than the repeat measurement uncertainty of 3%. Calibration 
measurements did not vary between room and body temperature. More 
details on MOSFET calibration and commissioning are included in 
supplementary data. 
 
Clinical measurements 
For the 40 patient treatments, mean (and range) of prostate D90 values were 
17.1 Gy (16.2 Gy - 17.6 Gy) for boost treatments and 21.1 Gy (20.8 Gy - 
21.4 Gy) for monotherapy treatments. Mean (and range) of prostate volume 
and number of treatment needles was 35.6 cm3 (16.7 cm3 - 55.7 cm3) and 
15.8 (10 - 19) respectively. Mean (and range) of dose at the MOSFET 
position was 17.7 Gy (15.2 Gy - 20.7 Gy) for boost treatments and 21.8 Gy 
(20.1 Gy - 26.4 Gy) for monotherapy treatments. 
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Considering mean values for the 40 patients, the total plan measured 
MOSFET reading was 6.4% lower than predicted (range +5.8% to -14.6%). 
Figure 1 shows all patient measurements in terms of absolute measured 
dose. Figure 2a shows one example measurement curve. Mean per-needle 
reading for the 40 patients was also 6.4% lower than prediction with 
standard deviation 17.3% and range -129% to +185%. The mean total plan 
energy dependence correction applied was 1.6% (range 0.5% - 3.2%). The 
mean per-needle energy dependence correction applied was 1.3% (range -
2.3% - 4.9%).   
 
Monte Carlo simulations 
MC simulations showed that the dose at the MOSFET position was on 
average -1.6% compared to the dose predicted by the TPS (mean for 10 
patients, range -1.0% to -2.0%).  
 
Analysis of post-treatment imaging 
Post-treatment TRUS images showed either minimal difference in needle 
positions or some posterior movement of the more posterior needles. In all 
cases needle displacements were <2 mm. In the post treatment 
reconstructions on average the dose at the MOSFET position was -1.8% 
compared to the original treatment plan (mean for 20 patients, range +0.9% 
to -5.3%). 
 
Evaluation of error detection thresholds 
Figure 2b shows an example of the predicted and measured readings 
compared to uncertainty thresholds. One out of 40 plans (2.5%) and 28 out 
of 628 (4.5%) needles exceeded the k=2 error detection threshold in the 
retrospective analysis. The plan outside it's threshold measured -12.1% 
compared to a threshold of ±11.8%. Post-treatment images for this patient 
showed dose reduction at the MOSFET position of 3.8%. The 28 needles 
outside the thresholds were in 16 patient plans and tended to have low 
predicted readings with mean 59.0 mV (range 5.1 mV - 153.2 mV) 
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compared to mean for all needles 106.5 mV and/or low absolute differences 
with 19/28 having measurement difference less than 20mV (~0.2 Gy) and 
27/28 having measurement difference less than 50mV (~0.5 Gy). Individual 
cases for needles with >20mV measurement difference and outside the 
uncertainty threshold were investigated retrospectively and in the majority 
of cases were likely to be due to needle reconstruction errors, although it is 
not possible to absolutely confirm this as is difficult to definitively identify 
a needle location in retrospective analysis of TRUS images. Four needles 
had a measurement difference of >100 mV (~1 Gy) from prediction yet 
were within the error threshold due to close proximity with the MOSFET. 
 
Discussion 
 
This study has investigated IVD in HDR prostate brachytherapy in a 
retrospective analysis of clinical measured data for 40 patients. Overall the 
IVD results give confidence in the accuracy of dose delivery. After applying 
the corrections from the MC simulation and post-treatment imaging 
investigations, the mean difference between measured and predicted total 
plan reading is -3.0% and the largest difference is -11.2%. Comparable 
measurements were made by Suchowerska et al [6] using a scintillation 
detector in the urethral catheter for CT planned treatments and achieved 
maximum deviation from planned dose of -9% for 10 patients (mean 
deviation was not stated but from the data presented can be calculated to be 
-3.3%) and also by Seymour et al [7] using a diode array in the rectum for 
28 patients finding 95% of measurements agreeing with predicted dose 
within ±20%. In this study the MOSFET was placed in an additional needle 
which gives a stable position that can be accurately reconstructed. However 
a limitation is that for very small prostates it can be difficult to find a 
suitable empty template position that does not risk the MOSFET needle 
perforating the urethra and on approximately five occasions over the period 
of this study we did not perform IVD for this reason. 
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MC simulations showed that steel needles reduced dose at the MOSFET 
position by 1.6% which is comparable to a study by Gaudreault et al [24] 
which found dose reduction of 1.3%. Needle movement in TRUS planning 
was investigated by Milickovic et al [23] who found an average reduction in 
urethra D0.1cm3 of 2.1% compared to a point dose reduction at the 
MOSFET position (generally close to the urethra) of 1.8% in this study. 
MOSFET measurements were ~3% low after these corrections had been 
applied. This apparently systematic difference could be due to an as yet 
undetected error in the MOSFET commissioning/calibration process or 
limitations in ultrasound reconstruction accuracy - the probe remains in the 
rectum during treatment but there could be differences in implant position 
compared to image acquisition where the probe is being moved through the 
rectum and compressing the prostate. 
  
This study has investigated the feasibility of real-time IVD to detect errors 
during treatment. This requires estimation of measurement uncertainties on 
a per-needle basis. Per-needle position uncertainty dominates and it is 
important to avoid falsely detecting an error for needles that are close to the 
MOSFET so tend to contribute a large proportion of the total dose, and only 
require a small positional shift to generate a large change in the MOSFET 
reading. It can be hard to position the MOSFET needle in a low dose 
gradient region, particularly for small prostates, and the MOSFET reading 
can be dominated by the contribution of a single needle with large 
associated uncertainties (in the worst case in this study ~1/3 of the total plan 
dose to the MOSFET was contributed from a single needle).  
 
Position uncertainty was estimated using an inverse square approximation 
for a position tolerance of 1mm. This method is simple to implement in a 
spreadsheet and could easily be calculated between plan approval and 
treatment delivery. Kertscher et al [15] used random position error 
simulations to estimate position uncertainties in a statistical manner and 
found k=1 position uncertainties up to 15.9% compared to 55.1% in this 
study, however the closest source-detector position was 6 mm compared to 
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2.7 mm in this study. Although large position uncertainties were derived for 
some needles in this study these were calculated using position shifts of 
1mm which would not be clinically significant [23]. For 91% of the needles 
analysed, the position uncertainty was < 20%.  
 
In this study ~5% of needle measurements exceeded the error threshold 
which is appropriate for a k=2 uncertainty level. The majority of these 
needles had low absolute mV predicted readings, therefore the uncertainty 
calculation could be under-estimating uncertainty for low readings. To 
reduce false positive errors a real-time monitoring method should also look 
at the absolute effect of any measurement difference as many of the needle 
measurements that exceeded the error threshold in percentage terms were 
only contributing a small amount to the total MOSFET dose.  
 
A limitation of this IVD technique is the single point of measurement, 
which means that some errors could go undetected, and makes it difficult to 
assess the overall dosimetric impact of errors that are detected. A connector 
swap error for two needles that are the same distance from the MOSFET 
will not be detected but could be clinically significant - for example if a 
heavily weighted peripheral needle and lowly weighted needle close to the 
urethra were swapped causing urethral overdose and prostate underdose. It 
may be possible to improve detection by analysing measurements for each 
20s reading provided by the MOSFET, rather than just per needle dose, or 
by using a device that provides more frequent or continuous measurements. 
The MOSFETs have limited lifetime and require significant commissioning 
work and individual, repeated calibrations but are relatively inexpensive and 
performing the IVD does not add significant time to our planning procedure.  
 
MOSFET IVD is a useful tool for dose delivery verification and suitable for 
routine clinical use. It can be used for real-time treatment monitoring as 
long as the limitations of the measurement technique and uncertainties are 
understood.  
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Table 1 Results of the uncertainty analysis. For variable uncertainty components the 
values shown are the mean with the minimum and maximum values in parentheses. 
Description Type Per needle 
uncertainty  
Total plan 
uncertainty  
MOSFET calibration (k=1) A 2.7 % 2.7 % 
Energy correction (k=1) A 1.7 % 0.3 % 
Angular dependence (k=1) A 3 % 0 % 
Source calibration (k=1)* A 2 % 2 % 
TPS dose calculation (k=1)* B 3 % 3 % 
Position uncertainty (k=1) B 13.0% (6.1% - 55.1%) 4.1% (2.7% - 7.2%) 
MOSFET reproducibility (k=1) A 3.4% (0.8% - 47%) 0.4% (0.3% - 0.5%) 
Mean total uncertainty (k=2)  31.9 % (18.3 % - 111 %) 12.3 % (10.6 % - 17.0 %) 
* Taken from Kirisits et al  [21]  
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Figure 1 Predicted versus measured dose at the MOSFET position for the 40 
HDR prostate brachytherapy patient treatments in this study. The error bars 
show the k=2 uncertainty for the predicted dose. 
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Figure 2 Measurement results for one patient (a) total accumulated 
MOSFET reading as the treatment is delivered (b) per needle MOSFET 
reading with error bars showing the k=2 uncertainty calculated for the 
predicted needle reading. 
19 
 
Fade in MOSFET sensitivity factor  
 
Calibration measurements were repeated 4-5 times through the MOSFET 
lifetime of 20000mV to assess fade in response with accumulated mV. Early 
experience showed that the MOSFET sensitivity factor decreases rapidly in 
the initial period of use. Therefore it was decided to pre-irradiate the 
MOSFETs to an accumulated mV of 2000 mV to improve the stability of 
the sensitivity factor. Eight MOSFETs were used in the study, and the 
sensitivity factor was found on average to decrease by 0.24 mV/Gy for 
every 1000 accumulated mV once the initial 2000 mV pre-irradiation had 
been completed. The measured MOSFET sensitivity factors are shown in 
Suppl Figure 1. 
 
 
Suppl Figure 1 MOSFET sensitivity factors from all MOSFET calibrations 
 
MOSFET energy dependence 
 
The MOSFET energy dependent response correction was determined from 
water tank measurements as described above, but varying the source-
MOSFET distance in the range 1 - 5 cm. For distances 1 - 3 cm the 
MOSFET was irradiated using 4 needles arranged at cardinal angles around 
the MOSFET needle, to minimize dose gradient at the MOSFET position, 
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for greater distances this was not possible due to the size of the template so 
a single source needle was used. 
 
The ratio of MOSFET measurement to the measurement predicted from the 
MOSFET sensitivity factor using the dose calculated by the TPS was used 
to determine the MOSFET response relative to the calibration distance of 
1.5 cm. A linear fit of response versus distance was used to determine the 
energy dependence correction. Suppl Figure 2 shows the results. Based on 
this a 2.6% cm-1 correction was applied to MOSFET predicted readings to 
correct for the energy dependence. 
 
Suppl Figure 2 Variation of response relative to response at 15mm due to MOSFET 
energy dependence 
 
MOSFET reproducibility uncertainty 
 
Measurement reproducibility was tested by calculating the standard error of 
5 repeat measurements at dose levels of approximately 0.1 Gy, 0.5 Gy, 1 
Gy, 2 Gy and 4Gy. A power curve fit was applied to the results (shown in 
Suppl Figure 3) and the percentage reproducibility uncertainty was found to 
be 116.4(R)-0.756 where R is the reading in mV. 
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Suppl Figure 3 Standard error in repeated MOSFET measurements against size of 
reading. 
 
Simple example of position uncertainty calculation 
 
Suppose the MOSFET is at co-ordinate (0,0,0) and there are two catheters 
with the source positions and dose contributions shown in Suppl Table 1. 
For each individual source position, the position uncertainty is estimated by 
taking the average of the inverse square law correction for r±1 mm (for 
example if r=10 mm then the uncertainty is the mean of ((11/10)2 - 1) and 
((10/9)2 - 1)). To estimate the position uncertainty per-needle, each source 
position uncertainty is weighted by the dose contribution for that source 
position as a proportion of the total for the needle, and the sum of the 
weighted source position contributions gives the per-needle uncertainty.  
 
The position uncertainty for the total plan dose is estimated using the same 
method, except that the position uncertainty from each source is weighted 
by the dose contribution for that source position as a proportion of the total 
plan dose. The position uncertainty for the plan is the sum of the weighted 
source position contributions divided by the square root of the number of 
needles in the plan. 
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Suppl Table 1 Position uncertainty calculation example. (x,y,z) are the source position 
co-ordinates and r is the distance from the source to the MOSFET. The MOSFET is at 
(0,0,0). 
Needle x y z r Dose Position 
uncertainty 
Position 
uncertainty 
(weighted per 
needle) 
Position 
uncertainty 
(weighted 
per plan) 
1 10 0 5 11.18 1 0.196 0.065 0.022 
1 10 0 0 10.00 0.5 0.222 0.037 0.012 
1 10 0 -5 11.18 0.5 0.196 0.033 0.011 
1 10 0 -10 14.14 1 0.152 0.051 0.017 
Total 
for 
needle 1 
      
0.186  
         
2 
-20 10 5 22.91 1 0.091 0.015 0.010 
2 
-20 10 0 22.36 2 0.094 0.031 0.021 
2 
-20 10 -5 22.91 2 0.091 0.030 0.020 
2 
-20 10 -10 24.49 1 0.085 0.014 0.009 
Total 
for 
needle 2 
      
0.091  
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Total 
for plan 
      
 
 
0.087 
 
 
 
 
